Price
Target price
-
-
-
-
-
?3.58
WKN: A3DM91 / Symbol: CASI / Name: CASI Pharmaceuticals Inc. / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
CASI Pharmaceuticals Inc. Stock
Currently there is a rather positive sentiment for CASI Pharmaceuticals Inc. with 3 Buy predictions and 0 Sell predictions.
With a target price of 3 € there is a hugely positive potential of 88.68% for CASI Pharmaceuticals Inc. compared to the current price of 1.59 €.
Our community identified positive and negative aspects for CASI Pharmaceuticals Inc. stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the CASI Pharmaceuticals Inc. stock. On the other hand our users think that "Customer and product portfolio" could be a problem in the future.
Pros and Cons of CASI Pharmaceuticals Inc. in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of CASI Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| CASI Pharmaceuticals Inc. | - | - | - | - | - | - | - |
| Ardelyx Inc. | 1.150% | 4.938% | 4.547% | -6.506% | 1.873% | 194.138% | -2.880% |
| Krystal Biotech | 1.290% | 8.522% | 17.592% | 14.742% | 32.194% | 183.380% | - |
| Evolus Inc | 0.880% | -1.724% | -5.785% | -51.695% | -45.714% | -12.977% | 91.019% |
Comments
CASI Pharmaceuticals (NASDAQ:CASI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Show more
Ratings data for CASI provided by MarketBeat
CASI Pharmaceuticals, Inc. (NASDAQ: CASI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Show more
Ratings data for CASI provided by MarketBeat
CASI Pharmaceuticals, Inc. (NASDAQ: CASI) had its price target lowered by analysts at HC Wainwright from $6.00 to $4.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CASI provided by MarketBeat